Is there a female counterpart to prostate cancer, despite the widespread belief that it only affects men? Although prostate cancer is commonly thought of as a disease that affects men, can it also affect women?
While women do not have a prostate gland in the same way men do, they do possess Skene’s glands, which share structural and functional similarities with the male prostate. These glands, located near the urethra, produce prostate-specific antigen (PSA) and play a role in the female reproductive and urinary systems.
Although it is uncommon, cancer can arise in these glands, resulting in a condition known as female urethral adenocarcinoma (FUA) or female prostate cancer. Because of its rarity, it is frequently misdiagnosed or discovered too late, so awareness is essential.
The “Female Prostate”: An Understanding of the Skene’s Glands
On either side of the female urethra are tiny structures known as Skene’s glands, or the female prostate. PSA, an enzyme involved in reproductive health, is produced by these glands, which function similarly to the male prostate. They are thought to aid in lubrication and potentially antimicrobial defense in the urinary tract, though their precise role is still being investigated. Skene’s glands resemble the male prostate, but they are much smaller, and they are much less frequently linked to cancer. However, because of a lack of knowledge and little research on the condition, malignancy can be aggressive and difficult to diagnose when it does occur.
How Can Skene’s Glands Cancer Develop in Women?
Female urethral adenocarcinoma (FUA) can result from cancerous growths in the Skene’s glands, even though traditional prostate cancer does not affect women. The glandular cells that line the Skene’s glands and surrounding structures are the source of this uncommon cancer. FUA is frequently understudied due to its low prevalence, and many cases are not identified until the cancer has spread.
Its development may be influenced by many risk factors, such as genetic predisposition, hormonal imbalances, and chronic inflammation. Skene’s gland cancer is rarely taken into account during medical evaluations, which results in a delayed diagnosis and worse outcomes than prostate cancer in men, which is frequently found through routine screening.
Female Prostate Cancer Symptoms
It can be challenging to diagnose Skene’s gland cancer because its early symptoms can resemble those of common gynecological or urinary disorders.
Typical symptoms consist of:
- Burning or pain when urinating
- Blood in the urine (hematuria)
- A noticeable lump close to the urethra
- Urination difficulties or increased urgency
- Pressure or discomfort behind the pubic bone
- unusual discharge from the vagina
Many women may receive incorrect initial diagnoses because these symptoms can be mistaken for conditions like interstitial cystitis or urinary tract infections (UTIs). Treatment becomes more difficult when the cancer reaches more advanced stages due to improper diagnosis delays.
Diagnosis of Female Prostate Cancer and Its Difficulties
Because Skene’s gland cancer is uncommon and its symptoms can mimic those of other gynecological or urinary conditions, diagnosing it can be challenging. Unlike PSA (Prostate-Specific Antigen) testing, which can detect prostate cancer in men, there is no standard screening test for female urethral adenocarcinoma (FUA).
- Doctors typically combine several methods to diagnose this condition:
- A pelvic examination is a physical examination used to check for lumps or abnormalities near the urethra.
- Imaging Tests: Abnormal growths can be seen with MRIs, CT scans, and ultrasounds.
- Biopsy: A tissue sample is taken to confirm malignancy.
Cystoscopy: A small camera is inserted into the urethra to look for tumors.
Inadequate early detection tools often result in late-stage diagnoses, which reduces the chances of successful treatment. Because the symptoms of persistent urinary problems are vague, women should consult a doctor to rule out serious conditions like cancer.
Treatment Options for Skene’s Gland Cancer
Treatment for female prostate cancer varies according to the stage of the disease and whether it has spread outside of the Skene’s glands. Some of the most widely used techniques are:
Surgery: The primary treatment involves removing the tumor. A section of the bladder or urethra may also need to be removed in more extreme situations.
- Radiation therapy: High-energy radiation is used to kill cancer cells and is typically used after surgery to prevent recurrence.
- Hormonal Therapy: Because some tumors are hormone-sensitive, medications that block estrogen or androgen activity may be used.
- Chemotherapy: Chemotherapy can help manage symptoms and slow the progression of cancer if it has spread.
- There are generic versions of Zytigao and Xtandi available for hormonal therapy in more severe cases. Patients may consider generic versions if they are looking for less costly options.
- Each treatment plan is tailored to the patient’s condition. Because early diagnosis significantly improves the success rate, women with persistent urinary symptoms need to have a proper medical evaluation.
Survival and Prognosis Rates
Skene’s gland cancer, also known as female urethral adenocarcinoma, usually has a poor prognosis because of the challenges in early detection. Because there is no routine screening and the symptoms often mimic those of more common urinary tract disorders, the cancer is typically found at an advanced stage.
- Survival rates are influenced by several factors:
- Diagnosis Stage: The prognosis for early-stage cancers is better than that of late-stage cancers, especially those that have spread.
- Tumor Aggressiveness: The ability of certain disease types to grow and spread quickly can impact the effectiveness of treatment.
- Response to Treatment: Long-term results are better for patients who react favorably to radiation therapy and surgery.
Generic versions of Zytiga or Generic version Xtandi are available at physician’s consultations to patients seeking less costly alternatives.
Although localized urethral adenocarcinoma has a generally good five-year survival rate, the prognosis deteriorates if the cancer spreads to adjacent organs or lymph nodes. Post-treatment monitoring and ongoing follow-ups are essential for increasing survival rates.
Promoting Early Diagnosis and Increasing Awareness
Skene’s gland cancer is frequently disregarded when talking about women’s health because it is incredibly uncommon. Improving early detection and treatment results requires raising awareness among the general public and medical professionals.
- A few crucial actions to increase awareness are:
- Educating Healthcare Professionals: When assessing urinary symptoms, many physicians might not think of Skene’s gland cancer right away. An earlier diagnosis may result from increased awareness and training.
- Urging Women to Seek Medical Attention: It is important to never disregard persistent urinary symptoms, such as painful urination or blood in the urine. Early medical advice-seeking can improve results.
- Research and Advocacy:
To better understand this uncommon cancer, create focused therapies, and investigate possible screening techniques, more research is required.
If initial treatments for infections or common conditions fail to alleviate persistent or unusual urinary symptoms, women should insist on additional testing. The best defense against this uncommon but dangerous illness is still early detection.
Generic forms of Zytiga or Xtandi might be accessible for people looking for efficient treatment. Get in touch via
or
Learn more about accessible treatment options